Biomedical subjects

Neil M Skjodt

Publications and source records attributed to Neil M Skjodt.

4 recordsLinked to original sources

PubMed2006

Improving adherence to a mechanical ventilation weaning protocol for critically ill adults: outcomes after an implementation program.

BACKGROUND: Despite multiple reminders, education sessions, and multidisciplinary team involvement, adherence to an evidence-based mechanical ventilation weaning protocol had been less than 1% in a general systems intensive care unit since implementation. OBJECTIVE: To assess the effectiveness of using an implementation program, the Model for Accelerating Improvement, to improve adherence and clinical outcomes after restarting a mechanical ventilation weaning protocol in an adult general systems intensive care unit. METHODS: A prospective comparative design, before and after implementation of the Model for Accelerating Improvement, was used with a consecutive sample of 129 patients and 112 multidisciplinary team members. Clinical outcomes were rate of unsuccessful extubations, rate of ventilator-associated pneumonia, and duration of mechanical ventilation; practice outcomes were staff's understanding of the mechanical ventilation weaning protocol, perceptions of the practice safety climate, and adherence to the weaning protocol. RESULTS: After the intervention, the rate of unsuccessful extubations decreased, and staff's understanding of and adherence to the weaning protocol increased significantly. The rate of ventilator-associated pneumonia, duration of mechanical ventilation, and staff's perceptions of the practice safety climate did not change significantly. CONCLUSION: Implementing the Model for Accelerating Improvement improved understanding of and adherence to protocol-directed weaning and reduced the rate of unsuccessful extubations.

Adolescent↗

PubMed2004

Best evidence in critical care medicine: treatment: vasodilatation with nitroprusside in symptomatic patients with severe aortic stenosis and congestive heart failure improves cardiac index.

Explore the source record for details and available documents.

Comment↗

PubMed2003

Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor.

Rofecoxib is a commonly used specific cyclo-oxygenase-2 (COX-2) inhibitor. Rofecoxib has high bioavailability, poor aqueous solubility, an elimination half-life suitable for daily administration and a volume of distribution approximating body mass. Species-specific, predominantly hepatic, metabolism occurs, with novel enterohepatic circulation in rats and O-glucuronidation by uridine diphosphate-glucuronosyl transferase (UGT) 2B7 and 2B15 in human liver microsomes. Discrepancies in studies of postoperative analgesia can be putatively explained by known pharmacokinetics. Changes in rofecoxib disposition and pharmacokinetics are evident between races, in elderly patients, in patients with chronic renal insufficiency and in patients with mild to moderate hepatic impairment. Despite the selective action of COX-2 inhibitors, there remains the potential for significant drug interactions. Rofecoxib has been shown to have interactions with rifampicin (rifampin), warfarin, lithium and angiotensin converting enzyme (ACE) inhibitors and theophylline. COX-2 inhibitors represent a major therapeutic advance in terms of gastrointestinal safety; however, long-term safety in other organ systems and with concomitant drug administration still remain to be proven.

Animals↗

PubMedDate not supplied

Drotrecogin alpha (activated) in two patients with the hantavirus cardiopulmonary syndrome.

Hantavirus cardiopulmonary syndrome (HCPS) is associated with rapid cardiopulmonary collapse from endothelial injury, resulting in massive capillary leak, shock and severe hypoxemic respiratory failure. To date, treatment remains supportive and includes mechanical ventilation, vasopressors and extracorporeal membrane oxygenation, with mortality approaching 50%. Two HCPS survivors initially given drotrecogin alpha (activated) (DAA) for presumed bacterial septic shock are described. Vasoactive medications were required for a maximum of 52 h, whereas creatinine levels and platelet counts normalized within seven to nine days. Given the similar presentations of HCPS and bacterial septic shock, empirical DAA therapy will likely be initiated before a definitive diagnosis of HCPS is made. Further observations of DAA in HCPS seem warranted.

Anti-Bacterial Agents↗